Is Mirum Pharmaceuticals, Inc. overvalued or undervalued?

As of 5 August 2021, the valuation grade for Mirum Pharmaceuticals, Inc. moved from does not qualify to risky, indicating increased caution regarding its financial health. The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 9.85, an EV to EBITDA of -44.55, and a ROE of -33.16%.
In comparison to its peers, Catalyst Pharmaceuticals, Inc. has a P/E ratio of 14.87 and an EV to EBITDA of 8.36, while CureVac NV shows a P/E of 6.06 and an EV to EBITDA of 2.79, both of which are significantly more favorable than Mirum's metrics. Despite Mirum's strong stock performance over the past year with a return of 56.86% compared to the S&P 500's 10.26%, the underlying financial ratios suggest that the stock is overvalued relative to its peers and its current financial situation.